Emergent Biosolutions (EBS)

May 14, 2025, 7:32 AM EDT - 21 days ago

Emergent BioSolutions to Participate in Upcoming Investor Conferences

May 7, 2025, 10:01 PM EDT - 4 weeks ago

Emergent BioSolutions Inc. (EBS) Q1 2025 Earnings Call Transcript

May 7, 2025, 4:05 PM EDT - 4 weeks ago

Emergent BioSolutions Reports First Quarter 2025 Financial Results

May 1, 2025, 5:07 PM EDT - 4 weeks ago

Emergent BioSolutions Reinforces Commitment to Opioid Emergency Preparedness Efforts in Canada Through Multi-Year Contract with Ontario Ministry of Health

Apr 22, 2025, 8:00 AM EDT - 6 weeks ago

Emergent BioSolutions to Report First Quarter 2025 Financial Results on May 7, 2025

Mar 31, 2025, 8:00 AM EDT - 2 months ago

Emergent BioSolutions Announces Stock Repurchase Program

Mar 20, 2025, 4:30 PM EDT - 2 months ago

Emergent BioSolutions New Hire Equity Grant Under NYSE Rule 303A.08

Mar 20, 2025, 8:06 AM EDT - 2 months ago

Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg

Mar 19, 2025, 4:30 PM EDT - 2 months ago

Emergent BioSolutions Finalizes Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 18, 2025, 8:00 AM EDT - 2 months ago

Emergent BioSolutions Announces Approximately $27 Million in Incremental Sales to Supply International Customers with Five Critical Medical Countermeasure Products

Mar 13, 2025, 8:29 AM EDT - 2 months ago

Emergent BioSolutions Reinforces its Commitment to Expanding Access to NARCAN® Nasal Spray by Supporting Organizations with New Opioid Overdose Preparedness Programs

Mar 12, 2025, 8:00 AM EDT - 3 months ago

Emergent BioSolutions and Rocketvax Announce Investment Agreement and Pursuit of a Strategic Relationship for Next-Generation Product Candidates

Mar 10, 2025, 9:14 AM EDT - 3 months ago

Emergent BioSolutions Announces Sale of Baltimore-Bayview Manufacturing Site to Syngene International

Mar 3, 2025, 7:58 PM EST - 3 months ago

Emergent BioSolutions Inc. (EBS) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 4:23 PM EST - 3 months ago

Emergent BioSolutions Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 18, 2025, 8:55 AM EST - 3 months ago

Emergent BioSolutions to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Feb 7, 2025, 8:06 AM EST - 4 months ago

Emergent BioSolutions and Pro Football Legend Emmitt Smith Raise Awareness of Ready to Rescue Campaign Timed to the Big Game in New Orleans

Jan 16, 2025, 8:00 AM EST - 4 months ago

Enrollment Starts in Africa CDC-Led MpOx Therapeutic Study (MOSA)

Jan 14, 2025, 7:53 AM EST - 5 months ago

Emergent BioSolutions: Stock Is A Likely Winner In 2025

Jan 14, 2025, 7:30 AM EST - 5 months ago

Emergent BioSolutions Gains Exclusive Commercial Rights to KLOXXADO® (naloxone HCI) Nasal Spray from Hikma Pharmaceuticals

Jan 13, 2025, 9:27 AM EST - 5 months ago

Emergent BioSolutions Receives Contract Option Valued at Approximately $16.7 Million to Continue Development Collaboration with BARDA on Ebanga™ (ansuvimab-zykl) Treatment for Ebola

Jan 8, 2025, 7:45 AM EST - 5 months ago

Emergent BioSolutions to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025

Jan 8, 2025, 7:30 AM EST - 5 months ago

Emergent BioSolutions Announces Exercise of $20 Million Option to Supply U.S. Department of Defense with BioThrax® (Anthrax Vaccine Adsorbed)

Dec 2, 2024, 5:49 PM EST - 6 months ago

SIGA Technologies Vs Emergent BioSolutions: Product Portfolio And Future Outlook

SIGA

Nov 8, 2024, 9:25 AM EST - 7 months ago

Emergent BioSolutions: Stock Surging Post Q3 Earnings Thanks To Papa Magic

Nov 7, 2024, 2:06 PM EST - 7 months ago

Mpox Vaccine Player Emergent BioSolutions Stock Jumps On Upbeat Annual Forecast, Expects Smaller Losses In 2024

Nov 6, 2024, 10:08 PM EST - 7 months ago

Emergent BioSolutions Inc. (EBS) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 4:49 PM EST - 7 months ago

Emergent BioSolutions Supports New Clinical Trial Evaluating the Safety and Efficacy of Brincidofovir in Treating Mpox Virus Across Africa

Oct 23, 2024, 7:30 AM EDT - 8 months ago

Emergent BioSolutions to Release Third Quarter 2024 Financial Results and Conduct Conference Call on November 6, 2024

Oct 8, 2024, 5:32 PM EDT - 8 months ago

Emergent BioSolutions Demonstrates Commitment to Increasing Access & Awareness of NARCAN® Nasal Spray to Help Combat the Opioid Epidemic

Oct 4, 2024, 9:48 AM EDT - 8 months ago

Emergent BioSolutions: Strategic Shifts Present A Turnaround Scenario

Sep 26, 2024, 8:05 AM EDT - 8 months ago

Emergent BioSolutions Announces the Execution of Contract Options Valued at $67.4 Million to Procure Additional TEMBEXA® (brincidofovir) to Support National Preparedness Efforts

Sep 25, 2024, 10:33 AM EDT - 9 months ago

Emergent BioSolutions Confirms Orders Worth $400M Related To Smallpox, Mpox Vaccines

Sep 25, 2024, 7:07 AM EDT - 9 months ago

Emergent BioSolutions Confirms Approximately $400 million in Orders in 2024 & 2025 to Support Smallpox and Mpox Preparedness Efforts

Sep 12, 2024, 8:30 AM EDT - 9 months ago

Emergent BioSolutions Awarded Research and Development Option valued at $41.9 Million for continued Advanced Development and Procurement of Ebanga™ Treatment for Ebola

Sep 3, 2024, 7:08 AM EDT - 9 months ago

Emergent BioSolutions Successfully Refinances Debt & Further Strengthens Financial Profile

Aug 30, 2024, 6:45 PM EDT - 9 months ago

Upside for Emergent Bio if they can get Mpox vaccine rollout right, says Mizuho's Jared Holz

Aug 30, 2024, 8:16 AM EDT - 9 months ago

Emergent BioSolutions Expands Ready to Rescue Initiative to Support Widespread Opioid Emergency Preparedness

Aug 30, 2024, 7:43 AM EDT - 9 months ago

Mpox Vaccine: Emergent BioSolutions' Smallpox Vaccine Gets FDA Nod For Expanded Use For Individuals At High Risk Of Mpox Infection

Aug 30, 2024, 7:15 AM EDT - 9 months ago

Emergent BioSolutions Stock Soars as FDA Approves Mpox Vaccine

Aug 29, 2024, 7:21 PM EDT - 9 months ago

US FDA approves use of Emergent's smallpox vaccine for people at high risk of mpox

Aug 29, 2024, 6:53 PM EDT - 9 months ago

Emergent BioSolutions' ACAM2000®, (Smallpox and Mpox (Vaccinia) Vaccine, Live) Receives U.S. FDA Approval for Mpox Indication; Public Health Mpox Outbreak Continues Across Africa & Other Regions

Aug 20, 2024, 11:30 AM EDT - 10 months ago

Emergent BioSolutions Finalizes Sale of Baltimore-Camden Manufacturing Site to Bora Pharmaceuticals

Aug 19, 2024, 5:30 PM EDT - 10 months ago

Emergent to donate 50,000 vaccine doses to address mpox outbreak in Africa

Aug 19, 2024, 5:10 PM EDT - 10 months ago

Emergent BioSolutions Responds to Mpox Public Health Emergency as Cases Surge in Africa

Aug 18, 2024, 9:00 AM EDT - 10 months ago

Emergent BioSolutions: Speculative Buy Amid Potential Monkeypox Vaccine Approval

Aug 15, 2024, 11:26 AM EDT - 10 months ago

Health stocks jump as WHO declares mpox global health emergency

Aug 15, 2024, 8:36 AM EDT - 10 months ago

Mpox outbreak: 5 stocks to watch out for as the emergency unfolds

GOVX SIGA

Aug 7, 2024, 11:47 AM EDT - 10 months ago

Vaccine Maker Emergent BioSolutions Expects Deeper Losses In 2024, Stock Sinks

Aug 6, 2024, 10:48 PM EDT - 10 months ago

Emergent BioSolutions Inc. (EBS) Q2 2024 Earnings Call Transcript